TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25109413

Group type: EXPERIMENTAL
Intervention: GSK1070806 (0.008 - 10 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23543663

Group type: EXPERIMENTAL
Intervention: Strontium ranelate (SR)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Ibandronate
Number of subjects: 89

Group type: COMPARATOR
Intervention: Calcium and vitamin D₃ supplements (Control)
Number of subjects: 89
Study: 20525742

Group type: EXPERIMENTAL
Intervention: Peer-assisted learning (PAL) using the GALS screening tool for MSS examination
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Peer-assisted learning (PAL) for trainees
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control group (standard MSS training)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Trainees (PAL)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Trainers (PAL)
Number of subjects: 209
Study: 18707870

Group type: EXPERIMENTAL
Intervention: Raltitrexed (8 cycles)
Number of subjects: 1921

Group type: COMPARATOR
Intervention: 5-FU/LV (6 cycles)
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: Raltitrexed
Number of subjects: 1921

Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 1921
Study: 19787287

Group type: EXPERIMENTAL
Intervention: PCD therapy
Number of subjects: 81

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 81

Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 81
Study: 16386096

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) testing using the A1cNow device
Number of subjects: 7758

Group type: COMPARATOR
Intervention: Central laboratory analysis using ion exchange high-performance liquid chromatography
Number of subjects: 7758
Study: 11561116

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg daily)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Nifedipine (40 mg daily)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg daily) in females with primary Raynaud's phenomenon
Number of subjects: 53

Group type: COMPARATOR
Intervention: Nifedipine (40 mg daily) in females with primary Raynaud's phenomenon
Number of subjects: 53
Study: 9115059

Group type: COMPARATOR
Intervention: Lidocaine (10 mg/mL)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Guanethidine (2 mg/mL)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nicardipine (0.2 mg/mL)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (0.3 mg/mL)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (1 microgram/mL)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: All vasodilators
Number of subjects: 6
Study: 7964960

Group type: EXPERIMENTAL
Intervention: Oral ondansetron 8 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3034469

Group type: EXPERIMENTAL
Intervention: Cilazapril 4 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg/day for 15 days
Number of subjects: 6
Study: 11487547

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 40
Study: 31404469

Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Therapy (OMTh) for 3 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Amitriptyline for 3 months
Number of subjects: 20
Study: 29987329

Group type: EXPERIMENTAL
Intervention: CGRP infusion (1.5 μg/min over 20 minutes)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CGRP infusion
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 26871700

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (BVB) 1.25 mg
Number of subjects: 41

Group type: COMPARATOR
Intervention: Triamcinolone (TA) 4 mg
Number of subjects: 41
Study: 25072617

Group type: EXPERIMENTAL
Intervention: 2-3 N(t)RTI + LPV/r
Number of subjects: 210

Group type: COMPARATOR
Intervention: RAL + LPV/r
Number of subjects: 210
Study: 23006898

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (stress doses)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Preoperative 2-AG levels
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Anandamide and 2-AG levels during the perioperative period
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 20391211

Group type: EXPERIMENTAL
Intervention: Anchoring heuristic
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Availability heuristic
Number of subjects: 468

Group type: COMPARATOR
Intervention: Control
Number of subjects: 468
Study: 17266687

Group type: EXPERIMENTAL
Intervention: Octreotide (0.3 mg) administered via continuous intravenous infusion for 6 hours, starting 1 hour before ERCP, with additional subcutaneous injections of 0.1 mg at 6 and 12 hours after infusion stopped.
Number of subjects: 832

Group type: COMPARATOR
Intervention: Placebo administered intravenously.
Number of subjects: 832
Study: 15483639

Group type: EXPERIMENTAL
Intervention: Chickpea bread (CHB)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Extruded chickpea bread (EXB)
Number of subjects: 12

Group type: COMPARATOR
Intervention: White bread (WB)
Number of subjects: 12
Study: 11752033

Group type: EXPERIMENTAL
Intervention: Combined analysis of 3D-Gadolinium MR angiography (3D-Gd-MRA) and cine phase-contrast flow measurement (PC-flow)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 3D-Gadolinium MR angiography (3D-Gd-MRA)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 43
Study: 9469172

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral pain management program
Number of subjects: 22

Group type: COMPARATOR
Intervention: Attention/support control treatment
Number of subjects: 22
Study: 8593922

Group type: EXPERIMENTAL
Intervention: Des(64,65)-proinsulin (DPRO) at doses of 0.1, 0.15, 0.2 U/kg
Number of subjects: 9

Group type: COMPARATOR
Intervention: NPH-insulin at doses of 0.2, 0.3, 0.4 U/kg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Des(64,65)-proinsulin (DPRO)
Number of subjects: 9
Study: 2664509

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (325 mg every other day)
Number of subjects: 22071

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22071
Study: 1115339

Group type: EXPERIMENTAL
Intervention: AH 8165, 1 times 25 mg/kg
Number of subjects: 240

Group type: COMPARATOR
Intervention: Suxamethonium, 1 mg/kg
Number of subjects: 240
Study: 31832912

Group type: EXPERIMENTAL
Intervention: Safety promotion intervention (n=91)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Attention-control group (n=186)
Number of subjects: 277
Study: 31511452

Group type: EXPERIMENTAL
Intervention: Couple education program focusing on coparenting, consisting of two interactive classes and a short video.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard childbirth education classes (control group).
Number of subjects: 21
Study: 28679142

Group type: EXPERIMENTAL
Intervention: 4,000 IU of vitamin D
Number of subjects: 90

Group type: COMPARATOR
Intervention: 1,000 IU of vitamin D
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 25497244

Group type: EXPERIMENTAL
Intervention: Apixaban (transitioning to VKA)
Number of subjects: 13397

Group type: COMPARATOR
Intervention: Warfarin (continuing on VKA)
Number of subjects: 13397

Group type: COMPARATOR
Intervention: Warfarin (for warfarin-naive patients)
Number of subjects: 13397
Study: 23381685

Group type: EXPERIMENTAL
Intervention: Transdiagnostic cognitive‐behavioral therapy intervention (up to 18 weeks)
Number of subjects: 0
Study: 22180523

Group type: EXPERIMENTAL
Intervention: LPV/r + RAL
Number of subjects: 206

Group type: COMPARATOR
Intervention: LPV/r + TDF/FTC
Number of subjects: 206
Study: 19658033

Group type: EXPERIMENTAL
Intervention: Interventions offered in the parent clinical trial
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Employment status
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: History of violent impulses and arrest
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Drug treatment received
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Coping strategies
Number of subjects: 68
Study: 16372352

Group type: EXPERIMENTAL
Intervention: Inhaled recombinant human alpha(1)-antitrypsin (rAAT) 500 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Inhaled recombinant human alpha(1)-antitrypsin (rAAT) 250 mg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Inhaled recombinant human alpha(1)-antitrypsin (rAAT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 14526711

Group type: EXPERIMENTAL
Intervention: Acupuncture; details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups; details not specified.
Number of subjects: 0
Study: 10539706

Group type: EXPERIMENTAL
Intervention: Spira Elektro 4 jet nebulizer with budesonide (0.5 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Spira Ultra ultrasonic nebulizer with budesonide (0.5 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Spira Elektro 4 jet nebulizer with terbutaline (5.0 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Spira Ultra ultrasonic nebulizer with terbutaline (5.0 mg)
Number of subjects: 10
Study: 8800583

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 23

Group type: COMPARATOR
Intervention: Celiprolol
Number of subjects: 23

Group type: COMPARATOR
Intervention: Doxazosin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 23

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 23
Study: 1863505

Group type: EXPERIMENTAL
Intervention: iopentol
Number of subjects: 61

Group type: COMPARATOR
Intervention: iohexol
Number of subjects: 61
Study: 6846920

Group type: EXPERIMENTAL
Intervention: Albuterol (100 and 200 micrograms)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Isoproterenol (70 and 140 micrograms)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31416352

Group type: EXPERIMENTAL
Intervention: Non-native Norwegian speakers
Number of subjects: 238

Group type: COMPARATOR
Intervention: Native Norwegian speakers
Number of subjects: 238
Study: 29766403

Group type: EXPERIMENTAL
Intervention: Teacher involvement (measured through teacher-reports)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Depressive symptoms (measured through peer- and teacher-reports)
Number of subjects: 570
Study: 30255204

Group type: EXPERIMENTAL
Intervention: Posterior pillar mucosal suspension technique (Group A)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Bipolar cautery (Group B)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Cold dissection tonsillectomy (Group C)
Number of subjects: 121
Study: 27169809

Group type: EXPERIMENTAL
Intervention: Goal-setting + self-monitoring + feedback (GS + SM + F, n = 40)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Goal-setting + self-monitoring (GS + SM, n = 40)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Goal-setting only (GS, n = 44)
Number of subjects: 124
Study: 24722045

Group type: EXPERIMENTAL
Intervention: Family Intervention: Telephone Tracking
Number of subjects: 49

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 49
Study: 22318834

Group type: EXPERIMENTAL
Intervention: Fentanyl plus ketamine (Group FK)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl (Group F)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 18823336

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combination of glibenclamide and diclofenac
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 14
Study: 17155990

Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormone therapy (HT)
Number of subjects: 316
Study: 15819758

Group type: EXPERIMENTAL
Intervention: Imitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Viewing presentation of events
Number of subjects: 0
Study: 12111907

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9506874

Group type: EXPERIMENTAL
Intervention: CPH-82 (Reumacon)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Auranofin (Ridaura)
Number of subjects: 60
Study: 7825428

Group type: EXPERIMENTAL
Intervention: Contralateral acoustic stimulation
Number of subjects: 2

Group type: COMPARATOR
Intervention: No contralateral noise (baseline)
Number of subjects: 2
Study: 3137605

Group type: EXPERIMENTAL
Intervention: DL-threo-3,4-dihydroxyphenylserine (DOPS) 1 g dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 0
Study: 30131330

Group type: EXPERIMENTAL
Intervention: '11+ Kids' injury prevention programme
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Usual warmup
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Countrywide implementation of '11+ Kids'
Number of subjects: 1002
Study: 29675430

Group type: EXPERIMENTAL
Intervention: PFD + M-DDO
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ketanserin
Number of subjects: 0
Study: 25989386

Group type: EXPERIMENTAL
Intervention: Small covered transjugular intrahepatic portosystemic stent-shunt (TIPS) (8 mm; n = 90)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Medical reduction of portal pressure (propranolol and isosorbide-5-mononitrate; n = 95)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Medical treatment before hemodynamic control
Number of subjects: 185

Group type: COMPARATOR
Intervention: Responders to medical treatment
Number of subjects: 185

Group type: COMPARATOR
Intervention: Nonresponders to medical treatment (variceal band ligation)
Number of subjects: 185

Group type: COMPARATOR
Intervention: TIPS placement during follow-up evaluation
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: TIPS and medical treatment
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: TIPS
Number of subjects: 185
Study: 23577819

Group type: EXPERIMENTAL
Intervention: Anterior ultrasound-guided superior hypogastric plexus neurolysis
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral morphine
Number of subjects: 50
Study: 21160196

Group type: EXPERIMENTAL
Intervention: Droperidol (2.5 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tropisetron (2.5 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no prophylactic antiemetic treatment)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tropisetron
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study: 19589122

Group type: EXPERIMENTAL
Intervention: Manidipine 20 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 64
Study: 17575270

Group type: EXPERIMENTAL
Intervention: Risk score predictive of major bleeding after PCI
Number of subjects: 7058

Group type: EXPERIMENTAL
Intervention: Risk model validation
Number of subjects: 7058
Study: 15510018

Group type: EXPERIMENTAL
Intervention: H. pylori antibody testing by ELISA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Immunohistochemical analysis with H. pylori antibody
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison of H. pylori antibodies by ELISA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison of biopsy specimens by immunohistochemical staining
Number of subjects: 30
Study: 12964220

Group type: EXPERIMENTAL
Intervention: Mepiform Safetac (one 24‐hour application)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mepiform Safetac (three x 24‐hour applications)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Mepilex Border Safetac (three x 24‐hour applications)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Duoderm Extra Thin (three x 24‐hour applications)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Allevyn Adhesive (three x 24‐hour applications)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Biatain Adhesive (three x 24‐hour applications)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Tielle Hydropolymer Dressing (three x 24‐hour applications)
Number of subjects: 32
Study: 9154761

Group type: EXPERIMENTAL
Intervention: MAGE-1 protein detection in gliomas
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: MAGE-4 protein detection in gliomas
Number of subjects: 28

Group type: COMPARATOR
Intervention: MAGE-1 protein detection in non-glioma tumors
Number of subjects: 28

Group type: COMPARATOR
Intervention: MAGE-4 protein detection in non-glioma tumors
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cellular MAGE-1 protein detection in glioblastoma cells
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: MAGE-4 protein confirmation
Number of subjects: 28
Study: 7955262

Group type: EXPERIMENTAL
Intervention: Isradipine (n = 90)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Sodium nitroprusside (n = 87)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 177

Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 177
Study: 3110819

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2529048

Group type: EXPERIMENTAL
Intervention: Intranasal sufentanil (15 micrograms)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intravenous sufentanil (15 micrograms)
Number of subjects: 16
Study: 30394507

Group type: EXPERIMENTAL
Intervention: Atherectomy treatment in diabetic patients (DM)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Atherectomy treatment in non-diabetic patients (nDM)
Number of subjects: 204
Study: 30719850

Group type: EXPERIMENTAL
Intervention: Occlutech Figulla Flex II Occluder (OFFII)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Amplatzer Septal Occluder (ASO)
Number of subjects: 176
Study: 28499022

Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Postcontrast T1-weighted imaging feature (information correlation)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Postcontrast T1-weighted imaging features
Number of subjects: 291
Study: 25555381

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) administration of Zostavax
Number of subjects: 354

Group type: COMPARATOR
Intervention: Subcutaneous (SC) administration of Zostavax
Number of subjects: 354
Study: 22523117

Group type: EXPERIMENTAL
Intervention: LC-MS/MS method for detection of podocyte-specific tryptic peptides
Number of subjects: 19
Study: 25885375

Group type: EXPERIMENTAL
Intervention: Palonosetron
Number of subjects: 60

Group type: COMPARATOR
Intervention: Palonosetron plus dexamethasone
Number of subjects: 60
Study: 19244878

Group type: EXPERIMENTAL
Intervention: rhPDGF‐BB + beta‐TCP + a wound healing dressing
Number of subjects: 6

Group type: COMPARATOR
Intervention: CTG
Number of subjects: 6
Study: 17112693

Group type: EXPERIMENTAL
Intervention: Psidii guajavae folium extract 6 mg/day
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Psidii guajavae folium extract 3 mg/day
Number of subjects: 197

Group type: COMPARATOR
Intervention: Ibuprofen 1200 mg/day
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo 3 mg/day
Number of subjects: 197
Study: 15086613

Group type: EXPERIMENTAL
Intervention: Desensitising toothpaste (SA)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Non-desensitising toothpaste (F)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash (CHX)
Number of subjects: 6

Group type: COMPARATOR
Intervention: No treatment group (P)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Desensitising toothpaste (SA) with/without OJ
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: In-office product (DS)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Desensitising toothpaste (SC)
Number of subjects: 6
Study: 11343004

Group type: EXPERIMENTAL
Intervention: Coronary care‐trained nurse (CCTN) present during ED hours
Number of subjects: 893

Group type: COMPARATOR
Intervention: No coronary care‐trained nurse (CCTN) present during ED hours
Number of subjects: 893
Study: 9562159

Group type: EXPERIMENTAL
Intervention: Resistance exercise (45 minutes of lifting three sets of 10 repetitions at 75% of one repetition maximum)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quiet rest (sitting quietly in a room free from distractions)
Number of subjects: 0
Study: 8202883

Group type: EXPERIMENTAL
Intervention: Nocturnal asthma patients (n=10)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Healthy control subjects (n=8)
Number of subjects: 18
Study: 3067313

Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg 4 times per day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Protriptyline (20 mg daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29566192

Group type: EXPERIMENTAL
Intervention: Vitamin D intervention (400 IU/d from vitamin D-fortified foods)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 51
Study: 26962834

Group type: EXPERIMENTAL
Intervention: End-stage renal disease (ESRD)
Number of subjects: 1068

Group type: COMPARATOR
Intervention: Cirrhotic patients without renal function impairment (Control)
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Cirrhotic patients with ESRD and recurrent complications
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Cirrhotic patients with ESRD and ascites
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Cirrhotic patients with ESRD and esophageal variceal bleeding (EVB)
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Cirrhotic patients with ESRD and hepatic encephalopathy (HE)
Number of subjects: 1068
Study: 25330161

Group type: EXPERIMENTAL
Intervention: QuantiFERON-TB Gold In-Tube (QFT-GIT) test
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: QFT-GIT test at baseline
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: QFT-GIT test at 12 months
Number of subjects: 975

Group type: COMPARATOR
Intervention: No ART
Number of subjects: 975

Group type: COMPARATOR
Intervention: IPT and early ART
Number of subjects: 975
Study: 22763668

Group type: EXPERIMENTAL
Intervention: 0.65 g/kg alcohol
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52